Genfit SA (GNFT)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Genfit SA ("Genfit" or "the Company") (NASDAQ: GNFT). The investigation concerns whether Genfit and certain of its officers and/or directors have violated federal securities laws.
On May 11, 2020, it was revealed that Genfit’s hepatitis treatment failed in a Phase 3 test. Investor’s Business Daily reported that “Genfit tested a drug called elafibranor in patients with nonalcoholic steatohepatitis, or NASH. However, the hepatitis treatment failed to resolve the symptoms of NASH without leading to worsening fibrosis.” Following this news, Genfit stock dropped over 50% during after-hours trading.
If you are aware of any facts relating to this investigation, or purchased Genfit shares, you can also contact Peretz Bronstein of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.